FDA grants Annexon monoclonal antibody ANX005 fast-track qualification
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
GBS is a rare acute autoimmune disease caused by nerve conduction damage caused by the patient's own immune system attacking his peripheral nervous systemToday (September 24), annexon Biosciences Bio
pharmaceutical(http://(http://announced that the U.SFDA(http://granted its targeted tonic protein C1q monoclonal antibody ANX005 fast-track eligibility to treat Guillain-Barr?Syndrome, GBS patientsPrior to that, the FDA had granted ANX005 orphan drug eligibilityabout C1q
C1q is an important component of the complement C1 and can participate in the activation of the complement classical pathwayC1q acts directly with neurons synapses in the central nervous system and causes neuronal damage and inflammationC1q can cause ophthalmology, autoimmune, and neurodegenerative diseasesAbout ANX005
Annexon developed tonic inhibitor ANX005 is a human-derived monoclonal antibody for C1q, mainly used to block the human immune early complement cascade process of the key protein C1q It not only blocks the activation of the whole classical path, but also maintains the integrity of other complement pathway functions ANX005 effectively blocks neuropathy through C1q and treats patients with GBS Annexon is also developing an application of ANX005 for the treatment of other autoimmune and neurodegenerative diseases
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
